Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success

• We developed a new endpoint, refractory graft-versus-host disease-free, relapse-free survival (rGRFS).• We validated current GRFS (cGRFS) using two distinct methods.• cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS.• The curves of cGRFS and rGRFS overlappe d after the first two years of post-transplant follow-up.• rGRFS can be easily calculated and analyzed with widely-used statistical approaches.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research